National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011-Reference-Cited by-同舟云学术

National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011

Published:2014-10 Issue:10 Volume:33 Page:1721-1727
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Conti Rena M.¹,Fein Adam J.²,Bhatta Sumita S.³

Affiliation:

1. Rena M. Conti ( ) is an assistant professor of health policy and economics in the Departments of Pediatrics and Health Studies at the University of Chicago, in Illinois.

2. Adam J. Fein is president of Pembroke Consulting, Inc., in Philadelphia, Pennsylvania.

3. Sumita S. Bhatta is an instructor in the Department of Medicine, Section of Hematology and Oncology, the University of Chicago.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference27 articles.

1. An economic evaluation of the war on cancer

2. Projections of the Cost of Cancer Care in the United States: 2010-2020

3. Prescription Drug Spending Trends In The United States: Looking Beyond The Turning Point

4. The Slowdown In Health Care Spending In 2009–11 Reflected Factors Other Than The Weak Economy And Thus May Persist

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Importance of Patient Health Insurance Coverage and Out-of-Pocket Costs for Genomic Testing in Oncologists' Treatment Decisions;JCO Oncology Practice;2024-01-09

2. A multi‐dimensional assessment of financial hardship of cancer patients using existing health system data;Cancer Medicine;2023-11-21

3. Association of Employment Disruptions and Financial Hardship Among Individuals Diagnosed with Cancer in the United States: Findings from a Nationally Representative Study;Cancer Research Communications;2023-09-12

4. Financial hardship and psychosocial well-being and quality of life among prostate cancer survivors in the United States;Urologic Oncology: Seminars and Original Investigations;2023-09

5. Financial toxicity of oral therapies in advanced prostate cancer;Urologic Oncology: Seminars and Original Investigations;2023-09